<div class="infobox infobox-gene">
| | |
|---|---|
| Gene Symbol | MCOLN1 |
| Full Name | Mucolipin TRP Cation Channel 1 |
| Aliases | TRPML1, ML4, MST034 |
| Chromosome | 19p13.2 |
| NCBI Gene ID | [57192](https://www.ncbi.nlm.nih.gov/gene/57192) |
| OMIM | [605248](https://omim.org/entry/605248) |
| Ensembl | [ENSG00000090674](https://ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000090674) |
| UniProt | [Q9GZU1](https://www.uniprot.org/uniprot/Q9GZU1) |
| Associated Diseases | Mucolipidosis type IV, [Alzheimer's disease](/diseases/alzheimers-disease), [Parkinson's disease](/diseases/parkinsons-disease) |
</div>
<div class="infobox infobox-gene">
| | |
|---|---|
| Gene Symbol | MCOLN1 |
| Full Name | Mucolipin TRP Cation Channel 1 |
| Aliases | TRPML1, ML4, MST034 |
| Chromosome | 19p13.2 |
| NCBI Gene ID | [57192](https://www.ncbi.nlm.nih.gov/gene/57192) |
| OMIM | [605248](https://omim.org/entry/605248) |
| Ensembl | [ENSG00000090674](https://ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000090674) |
| UniProt | [Q9GZU1](https://www.uniprot.org/uniprot/Q9GZU1) |
| Associated Diseases | Mucolipidosis type IV, [Alzheimer's disease](/diseases/alzheimers-disease), [Parkinson's disease](/diseases/parkinsons-disease) |
</div>
MCOLN1 encodes mucolipin-1 (TRPML1), a non-selective cation channel localized primarily to late endosomes and [lysosomes](/mechanisms/lysosomal-dysfunction). TRPML1 is the principal lysosomal calcium release channel, playing essential roles in lysosomal calcium signaling, [autophagy](/entities/autophagy), lysosomal exocytosis, membrane trafficking, and heavy metal homeostasis. Loss-of-function mutations cause mucolipidosis type IV (MLIV), a severe neurodegenerative lysosomal storage disorder, while emerging evidence implicates TRPML1 dysfunction in common neurodegenerative diseases including [Alzheimer's disease](/diseases/alzheimers-disease) and [Parkinson's disease](/diseases/parkinsons-disease).
MCOLN1 spans approximately 14 kb on chromosome 19p13.2 and contains 14 exons. Expression is regulated by [TFEB](/genes/tfeb) and [TFE3](/genes/tfe3), master transcription factors of the CLEAR (Coordinated Lysosomal Expression and Regulation) gene network, creating a positive feedback loop: TRPML1-mediated lysosomal calcium release activates calcineurin, which dephosphorylates [TFEB](/entities/tfeb), promoting its nuclear translocation and further MCOLN1 transcription[@medina2015].
TRPML1 is the primary mechanism for regulated calcium release from the lysosomal lumen. Lysosomal calcium concentration (~0.5 mM) is maintained by H+/Ca2+ exchangers, and TRPML1 activation generates local calcium microdomains essential for lysosomal fusion events (calcium-dependent SNARE-mediated membrane fusion), lysosomal exocytosis (plasma membrane repair and cellular waste secretion), and [TFEB](/genes/tfeb) activation (calcineurin-mediated dephosphorylation cascade)[@xu2015].
TRPML1 is critical for multiple steps of [autophagy](/mechanisms/autophagy-lysosomal-pathway). It promotes autophagosome-lysosome fusion via calcium-dependent ALG-2 activation and STX17-mediated SNARE complex assembly. TRPML1 drives lysosomal biogenesis through TFEB activation and is essential for autophagic lysosome reformation (ALR), generating the calcium signal needed for tubulation and fission of autolysosomes[@li2016].
TRPML1 regulates vesicular trafficking through the late endosomal-lysosomal compartment. Its activation promotes endosome-lysosome fusion, retrograde trafficking to the trans-Golgi network, cholesterol and sphingolipid export from lysosomes, and heavy metal (Fe2+, Zn2+) efflux from lysosomes[@dong2008].
TRPML1 contributes to lysosomal pH homeostasis by mediating cation efflux that dissipates the proton gradient. Loss of TRPML1 leads to lysosomal overacidification in some contexts, disrupting hydrolase activity and substrate degradation[@soyombo2006].
Biallelic loss-of-function mutations in MCOLN1 cause mucolipidosis type IV (MLIV; OMIM 252650), an autosomal recessive lysosomal storage disorder with prevalence of ~1:40,000 in the Ashkenazi Jewish population. MLIV presents with severe psychomotor retardation, visual impairment (corneal clouding, retinal degeneration), and progressive neurodegeneration. Neuropathology shows widespread lysosomal storage, thin corpus callosum, and progressive white matter loss[@schiffmann1998].
TRPML1 dysfunction is emerging as a contributor to [Alzheimer's disease](/diseases/alzheimers-disease) pathogenesis through endolysosomal [amyloid-beta](/proteins/amyloid-beta) accumulation (impaired TRPML1 activity reduces lysosomal clearance of Abeta42 aggregates), [tau](/proteins/tau) clearance deficits (autophagy impairment promotes [tau](/proteins/tau) accumulation), presenilin interactions ([PSEN1](/genes/psen1) mutations may alter lysosomal calcium through TRPML1-dependent mechanisms), and lipid dyshomeostasis (cholesterol and sphingolipid accumulation in AD lysosomes impairs TRPML1 gating)[@bae2014].
TRPML1 dysfunction intersects with multiple [Parkinson's disease](/diseases/parkinsons-disease) pathways. The [GBA1](/genes/gba1)-TRPML1 axis is critical: glucocerebrosidase deficiency causes GlcCer accumulation that directly inhibits TRPML1 channel activity. [LRRK2](/genes/lrrk2) kinase activity modulates endolysosomal TRPML1 function. TRPML1-dependent autophagy is essential for degrading [alpha-synuclein](/proteins/alpha-synuclein) aggregates, and TRPML1 contributes to [PINK1](/genes/pink1)/[Parkin](/genes/prkn)-mediated mitophagy completion[@tsunemi2019].
MCOLN1 is ubiquitously expressed, with notable enrichment in [microglia](/cell-types/microglia) (highest brain expression, critical for phagocytic clearance), [neurons](/entities/neurons) (autophagy-dependent survival requires TRPML1), [astrocytes](/cell-types/astrocytes) (lysosomal function in glymphatic clearance), and retinal pigment epithelium (high phagocytic load requires robust lysosomal function).
Allen Human Brain Atlas: [MCOLN1 expression](https://human.brain-map.org/microarray/search/show?search_term=MCOLN1)
TRPML1 is an attractive therapeutic target for neurodegeneration. TRPML1 agonists (ML-SA1, ML-SA5) are small molecules that enhance lysosomal function, showing neuroprotection in AD and PD models. AAV-MCOLN1 gene therapy rescues neurodegeneration in MLIV mouse models. TFEB activation provides indirect TRPML1 upregulation through CLEAR network engagement. Lipid-modifying therapies reducing sphingolipid/cholesterol accumulation can restore TRPML1 gating.
From the [SciDEX Exchange](/exchange) — scored by multi-agent debate
The following diagram shows the key molecular relationships involving MCOLN1 — Mucolipin-1 (TRPML1) discovered through SciDEX knowledge graph analysis: